Zorayr Manukyan

Efficacy and Safety of PF‐06651600 (Ritlecitinib), a Novel JAK3/TEC Inhibitor, in Patients With Moderate‐to‐Severe Rheumatoid Arthritis and an Inadequate Response to Methotrexate

Michael F. Robinson, Nemanja Damjanov, Bojana Stamenković et al. · Arthritis & Rheumatology · 2020 · 84 citations · Full text

Safety, tolerability, pharmacokinetics, and pharmacodynamics of PF-06650833, a selective interleukin-1 receptor-associated kinase 4 (IRAK4) inhibitor, in single and multiple ascending dose randomized phase 1 studies in healthy subjects

Spencer I. Danto, Negin Shojaee, Ravi Shankar Prasad Singh et al. · Arthritis Research & Therapy · 2019 · 61 citations · Full text

Reduced cerebral blood flow in older men with higher levels of blood pressure

Shari R. Waldstein, David M. Lefkowitz, Eliot L. Siegel et al. · Journal of Hypertension · 2010 · 46 citations · Full text

Central site monitoring: Results from a test of accuracy in identifying trials and sites failing Food and Drug Administration inspection

Anne S. Lindblad, Zorayr Manukyan, Tejashri Purohit-Sheth et al. · Clinical Trials · 2013 · 44 citations

HLA-C*04:01 Affects HLA Class I Heterozygosity and Predicted Affinity to SARS-CoV-2 Peptides, and in Combination With Age and Sex of Armenian Patients Contributes to COVID-19 Severity

Anahit Hovhannisyan, Vergine Madelian, Sevak Avagyan et al. · Frontiers in Immunology · 2022 · 33 citations · Full text